SynthesisJournal of Crohn's & colitis2026
Risk of intestinal cancer in Crohn's disease: re-analysis and meta-regression of population-based cohort studies.
Synthesis in Journal of Crohn's & colitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Colitis-associated colorectal carcinogenesis: molecular mechanisms and therapeutic potential.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe risk of intestinal malignancy in Crohn's disease (CD) varies across regions. Given the rising global cancer prevalence, this study aimed to summarize evidence and evaluate associations between CD and site-specific intestinal cancer risks.
methodsWe systematically searched PubMed, Embase, and Scopus from inception to July 10, 2025. All population-based epidemiological observational studies that investigated any outcome related to intestinal cancer in adults (the majority of participants >18 years of age), including individuals of any ethnicity or sex from all countries and settings that report observed and expected national cases, were included. Patients diagnosed with colorectal cancer (CRC) or small bowel cancer (SBC) less than 1 year after CD diagnosis, as well as papers that address cancer mortality while combining CD and ulcerative colitis outcomes, referral-center studies, and review articles, were excluded. We analyzed 27 population-based studies using restricted maximum-likelihood models; pooled standardized incidence ratios (SIRs) were calculated for CRC and SBC. Meta-regression explored the impact of cohort size, follow-up duration, calendar year, and disease location on risk estimates. Methodological quality was assessed with the modified Newcastle-Ottawa Scale.
resultsThe overall CRC SIR in CD patients was significantly elevated (SIR 2.20, 95% CI 1.69-2.86). Colon cancer (SIR 2.06, 95% CI 1.09-3.90) and rectal cancer (SIR 1.75, 95% CI 1.16-2.62) risks were higher, especially in colonic disease (SIR 3.29, 95% CI 1.66-6.50) and ileocolonic disease (SIR 4.13, 95% CI 2.14-7.94), while ileal disease exposed a milder risk (SIR 1.95, 95% CI 1.16-3.26). SBC SIR was markedly increased (SIR 17.18, 95% CI 9.93-29.73), particularly in ileal (SIR 44.85, 95% CI 12.93-155.54) and ileocolonic disease (SIR 21.44, 95% CI 5.13-89.62).
conclusionCD is associated with heightened CRC and SBC risks, varying by disease location. These findings underscore the need for tailored cancer screening and further research into the impact of environmental and genetic factors on cancer risk in CD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.